SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

Vanda Pharmaceuticals Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

(CUSIP Number)

Mihael Hristos Polymeropoulos
C/O Vanda Pharmaceuticals, 2200 Pennsylvania Avenue NW, Suite 300E
Washington, DC, 20037
202 734 3400

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

11/17/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No.

1	Name of reporting person Mihael Hristos Polymeropoulos
2	Check the appropriate box if a member of a Group (See Instructions) ☐ (a) ☐ (b)
3	SEC use only

	Source of funds (See Instructions)	
4	OO	
	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)	
5	☐	
	Citizenship or place of organization	
6	UNITED STATES	
Number of Shares Beneficially Owned by Each Reporting Person With:	Sole Voting Power	7
	3,102,251.00	
	Shared Voting Power	8
	0.00	
	Sole Dispositive Power	9
	3,102,251.00	
	Shared Dispositive Power	10
	0.00	
	Aggregate amount beneficially owned by each reporting person	
11	3,102,251.00	
	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)	
12	☐	
	Percent of class represented by amount in Row (11)	
13	5.01 %	
	Type of Reporting Person (See Instructions)	
14	IN	

SCHEDULE 13D

Item 1.	Security and Issuer
	Title of Class of Securities:
(a)	Common Stock, par value $0.001 per share
	Name of Issuer:
(b)	Vanda Pharmaceuticals Inc.
	Address of Issuer's Principal Executive Offices:
(c)	2200 Pennsylvania Avenue NW, Suite 300E, Washington , DISTRICT OF COLUMBIA , 20037.
Item 1 Comment:	This Schedule 13D relates to the Common Stock, par value $0.001 per share (the "Common Stock") of Vanda Pharmaceuticals Inc. (the "Issuer"). The address of the principal executive office of the Issuer is 2200 Pennsylvania Avenue NW,. Suite 300E, Washington, DC 20037, United States. This Schedule 13D is being filed pursuant to Rule 13d-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), to report that the beneficial ownership percentage of Mihael Hristos Polymeropoulos (the "Reporting Person") has increased to exceed five percent of the Issuer's outstanding Common Stock.
Item 2.	Identity and Background
(a)	Mihael Hristos Polymeropoulos
(b)	The address of the principal business and the principal office of the Reporting Person: C/O Vanda Pharmaceuticals Inc., 2200 Pennsylvania Avenue NW, Suite 300E, District of Columbia, Washington 20037
(c)	The principal occupation of the Reporting Person is serving as the President, Chief Executive Officer and Chairman of the Board of Directors of the Issuer.
(d)	During the last five years, the Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e) During the last five years, the Reporting Person has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f) The Reporting Person is a citizen of the United States of America.

Item 3. Source and Amount of Funds or Other Consideration

The Reporting Person acquired beneficial ownership of the shares of Common Stock reported herein (the "Shares") in connection with the Reporting Person's service as President and Chief Executive Officer of the Issuer. Specifically, the Reporting Person crossed the 5.0% beneficial ownership threshold on November 17, 2026 (the "Event Date") as a result of options to purchase 5,729 shares of Common Stock becoming exercisable within 60 days of the Event Date, which options were granted to the Reporting Person pursuant to the Issuer's Amended and Restated 2016 Equity Incentive Plan, as amended (the "Plan") as compensatory equity awards. No cash funds or other monetary consideration were paid by the Reporting Person in connection with the grant or vesting of such equity awards or the acquisition of beneficial ownership of the underlying shares upon such awards becoming exercisable within 60 days. The remaining shares were acquired either (i) upon the prior vesting and/or exercise or settlement of compensatory equity awards granted under the Plan or (ii) through open market purchases using personal funds.

Item 4. Purpose of Transaction

The information set forth in Item 3 of this Schedule 13D is incorporated herein by reference. The Reporting Person serves as President, Chief Executive Officer and Chairman of the Board of Directors of the Issuer. In such capacities, the Reporting Person may engage in communications with the Issuer's Board of Directors, members of management, other shareholders, financial and legal advisers and other parties regarding the Issuer, including but not limited to the Issuer's operations, governance and control. In addition, in these capacities, the Reporting Person may have influence over the corporate activities of the Issuer, including activities which may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. Except as set forth herein, the Reporting Person does not have any plans or proposals which relate to, or could result in, any of the matters referred to in paragraphs (a) through (j), inclusive, of the instructions to Item 4 of Schedule 13D. The Reporting Person may, at any time and from time to time, review or reconsider his position and/or change his purpose and/or formulate plans or proposals with respect thereto. The Reporting Person acquired beneficial ownership of the Shares for investment purposes and as compensation for services rendered as President and Chief Executive Officer of the Issuer, and intends to review his investment in the Issuer on a continuing basis. Accordingly, the Reporting Person may acquire additional Shares or other securities of the Issuer or sell or otherwise dispose of any or all of the Shares or other securities of the Company that the Reporting Person beneficially owns.

Item 5. Interest in Securities of the Issuer

(a) The information contained on the cover page of this Schedule 13D is incorporated herein by reference. As of the date hereof, the Reporting Person beneficially owns an aggregate of 3,102,251 shares of Common Stock, representing approximately 5.01% of the outstanding shares of Common Stock. The Reporting Person's aggregate beneficial ownership consists of: (i)1,587,984 shares of Common Stock held directly by the Reporting Person; and (ii)1,514,267 shares of Common Stock issuable upon the exercise of stock options that are currently vested and exercisable or will become vested and exercisable within 60 days of the date hereof. The percentage of beneficial ownership reported herein is calculated based upon 60,471,687 shares of Common Stock outstanding as of November 17, 2026, by the Issuer's transfer agent, plus 1,514,267 shares of Common Stock issuable upon the exercise of stock options held by the Reporting Person that are exercisable or will vest within 60 days of the date hereof, calculated in accordance with Rule 13d-3(d)(1)(i) under the Act.

(b) Number of shares as to which the Reporting Person has (i) sole power to vote or direct the vote: See Item 7 on the cover page(s) hereto. (ii) shared power to vote or direct the vote: See Item 8 on the cover page(s) hereto. (iii) sole power to dispose or to direct the disposition of: See Item 9 on the cover page(s) hereto. (iv) shared power to dispose or to direct the disposition of: See Item 10 on the cover page(s) hereto.

(c) Except as described in Item 3, the Reporting Person has not effected any transaction in the Shares Common Stock in the last 60 days.

(d) No other person is known to the Reporting Person to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares of the Issuer covered by this Schedule 13D.

(e) November 17, 2026

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

The information set forth in Items 3, 4, and 5 of this Schedule 13D is incorporated herein by reference. In the Reporting Person's capacity as President and Chief Executive Officer of the Issuer, the Reporting Person holds compensatory stock options and restricted stock units granted pursuant to the Plan and governed by standard form award agreements thereunder. Specifically, as of the date hereof, the Reporting Person holds: (i) stock options to purchase an aggregate of 1,520,000 shares of Common Stock at exercise prices ranging from $7.05 to $20.62 per share, of which 1,514,267 are vested and exercisable or will become vested and exercisable within 60 days of the date hereof, and 5,733 remain unvested and will vest on February 16, 2027, subject to the Reporting Person's continued service; (ii) 1,116,250 unvested RSUs, none of which will vest within 60 days of the date hereof and all of which will vest in accordance with their respective award agreements; and (iii) 175,000 unvested performance restricted stock units ("PSUs"), none of which will vest within 60 days of the date hereof and all of which will vest in accordance with their respective award agreements. In addition, pursuant to the Issuer's Stock Ownership Guidelines, the Reporting Person is required to maintain beneficial ownership of Common Stock having a value equal to at least six times the

Reporting Person's annual base salary. Except as described in this Schedule 13D, there are no contracts, arrangements, understandings, or relationships (legal or otherwise) between the Reporting Person and any other person with respect to any securities of the Issuer, including, but not limited to, transfer or voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.

Item 7. Material to be Filed as Exhibits.

Exhibit 99.1 Vanda Pharmaceuticals Inc. Amended and Restated 2016 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.23 to the Issuer's Registration Statement on Form S-8 (File No. 333-296555), filed with the SEC on June 5, 2026). Exhibit 99.2 Form of Notice of Stock Option Grant and Stock Option Agreement for Senior Management under the Vanda Pharmaceuticals Inc. Amended and Restated 2016 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.6 to the Issuer's Quarterly Report on Form 10-Q, filed with the SEC on November 9, 2023). Exhibit 99.3 Form of Restricted Stock Unit Award Agreement for Senior Management under the Vanda Pharmaceuticals Inc. Amended and Restated 2016 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 to the Issuer's Quarterly Report on Form 10-Q, filed with the SEC on May 8, 2025). Exhibit 99.4 Form of Performance Restricted Stock Unit Award Agreement under the Vanda Pharmaceuticals Inc. Amended and Restated 2016 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 to the Issuer's Current Report on Form 8-K, filed with the SEC on February 19, 2026).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Mihael Hristos Polymeropoulos

Signature:	/s/ Mihael Hristos Polymeropoulos
Name/Title:	Mihael Hristos Polymeropoulos President, Chief Executive Officer and Chairman of the Board
Date:	11/23/2026